Bichuetti, DB;
Franco, CA;
Elias, I;
Mendonca, ACR;
Diniz Carvalho, LF;
Diniz, DS;
Tur, C;
... Lobato de Oliveira, EM; + view all
(2018)
Multiple sclerosis risk perception and acceptance for Brazilian patients.
Arquivos de Neuro-Psiquiatria
, 76
(1)
pp. 6-12.
10.1590/0004-282X20170167.
Preview |
Text
0004-282X-anp-76-1-0006.pdf - Published Version Download (172kB) | Preview |
Abstract
The perception of multiple sclerosis (MS) severity and risk associated with therapies might influence shared decision making in different countries. We investigated the perception of MS severity and factors associated with risk acceptance in Brazil in 96 patients with relapsingremitting MS using a standardized questionnaire and compared this with two European cohorts. Multiple sclerosis was perceived as a very severe disease and the risk of developing progressive multifocal leukoencephalopathy due to natalizumab was seen as moderate to high. Seventy-six percent considered a risk of 1:1,000, or higher, an impediment for natalizumab use. Older age was the only variable associated with higher risk acceptance and our patients showed a more conservative profile than German and Spanish patients. Our patients perceived MS severity and progressive multifocal leukoencephalopathy risk similarly to elsewhere, but their willingness to take risks was more conservative. This should be considered when discussing therapeutic options and it might have an impact on guideline adaptations.
Type: | Article |
---|---|
Title: | Multiple sclerosis risk perception and acceptance for Brazilian patients |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1590/0004-282X20170167 |
Publisher version: | http://doi.org/10.1590/0004-282X20170167 |
Language: | English |
Additional information: | This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
Keywords: | multiple sclerosis; natalizumab; risk-taking; risk assessment, decision making. |
UCL classification: | UCL UCL > Provost and Vice Provost Offices UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neuroinflammation |
URI: | https://discovery.ucl.ac.uk/id/eprint/10043979 |
Archive Staff Only
View Item |